Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

KaloBios escapes liquidation, majority bought out by Shkreli-led investor group

Executive Summary

Martin Shkreli (former hedge fund manager who is now CEO of private biotech Turing Pharmaceuticals AG) led an investor group that acquired 70% of publicly traded KaloBios Pharmaceuticals Inc. (oncology antibodies) for $4.4mm, or approximately $1.51 per share (a 21% discount to the ten-day average prior to KaloBios stating it would reduce its workforce and seek strategic alternatives). Shkreli is now chairman and CEO of KaloBios.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Acquisition
    • Buy-out
    • Partial Acquisition

Related Companies

UsernamePublicRestriction

Register